{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:16:32Z","timestamp":1780359392837,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14094-0","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:35:47Z","timestamp":1769686547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access"],"prefix":"10.1186","volume":"26","author":[{"given":"Surasit","family":"Lochid-amnuay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnachai","family":"Kongsakon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"14094_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon: Int Agency Res Cancer 2020, 20182020."},{"key":"14094_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/cncr.32887","volume":"126","author":"O Ginsburg","year":"2020","unstructured":"Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, Gyawali B, McCormack V, de McLaughlin M, Mehrotra R. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126:2379\u201393.","journal-title":"Cancer"},{"key":"14094_CR3","doi-asserted-by":"publisher","first-page":"1355353","DOI":"10.3389\/fonc.2024.1355353","volume":"14","author":"S Ali-Thompson","year":"2024","unstructured":"Ali-Thompson S, Daly GR, Dowling GP, Kilkenny C, Cox L, McGrath J, AlRawashdeh MM, Naidoo S, Power C, Hill AD. A bibliometric analysis of HER2-positive breast cancer: 1987\u20132024. Front Oncol. 2024;14:1355353.","journal-title":"Front Oncol"},{"issue":"9","key":"14094_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/07357907.2010.496759","volume":"28","author":"KA Cronin","year":"2010","unstructured":"Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28(9):963\u20138.","journal-title":"Cancer Invest"},{"key":"14094_CR5","doi-asserted-by":"publisher","first-page":"102527","DOI":"10.1016\/j.ctrv.2023.102527","volume":"115","author":"V Mueller","year":"2023","unstructured":"Mueller V, Bartsch R, Lin NU, Montemurro F, Pegram MD, Tolaney SM. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treat Rev. 2023;115:102527.","journal-title":"Cancer Treat Rev"},{"key":"14094_CR6","doi-asserted-by":"publisher","first-page":"103952","DOI":"10.1016\/j.critrevonc.2023.103952","volume":"184","author":"CM Hassing","year":"2023","unstructured":"Hassing CM, Nielsen DL, Knoop AS, Tvedskov THF, Kroman N, Laenkholm A-V, Juhl CB, Kuemler I. Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis. Crit Rev Oncol\/Hematol. 2023;184:103952.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"14094_CR7","doi-asserted-by":"publisher","first-page":"e000810","DOI":"10.1136\/bmjonc-2025-000810","volume":"4","author":"HM Earl","year":"2025","unstructured":"Earl HM, Hiller L, Dunn JA, Patel M, Conte P, D\u2019Amico R, Guarneri V, Joensuu H, Huttunen T, Hatzidaki D. Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data. BMJ Oncol. 2025;4(1):e000810.","journal-title":"BMJ Oncol"},{"key":"14094_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.vhri.2018.08.004","volume":"18","author":"R Kongsakon","year":"2019","unstructured":"Kongsakon R, Lochid-Amnuay S, Kapol N, Pattanaprateep O. From research to policy implementation: trastuzumab in early-stage breast cancer treatment in Thailand. Value Health Reg Issues. 2019;18:47\u201353.","journal-title":"Value Health Reg Issues"},{"issue":"7","key":"14094_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1999.17.7.1974","volume":"17","author":"TW Jacobs","year":"1999","unstructured":"Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2\/neu in breast cancer. J Clin Oncol. 1999;17(7):1974\u20131974.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14094_CR10","doi-asserted-by":"publisher","first-page":"e035389","DOI":"10.1136\/bmjopen-2019-035389","volume":"10","author":"E Roman","year":"2020","unstructured":"Roman E, Cardoen B, Decloedt J, Roodhooft F. Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients. BMJ Open. 2020;10(7):e035389.","journal-title":"BMJ Open"},{"key":"14094_CR11","doi-asserted-by":"crossref","unstructured":"Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, Al-Masri Y. Dual Anti-HER2 therapy vs trastuzumab alone with neoadjuvant anthracycline and taxane in HER2-positive early-stage breast cancer: real-world insights. Biol Targets Ther 2025:59\u201371.","DOI":"10.2147\/BTT.S468650"},{"key":"14094_CR12","volume-title":"Guideline for health technology assessment in Thailand, revised edition 2021","author":"Health Intervention and Technology Assessment Program (HITAP)","year":"2021","unstructured":"Health Intervention and Technology Assessment Program (HITAP). Guideline for health technology assessment in Thailand, revised edition 2021. Nonthaburi: Health Intervention and Technology Assessment Program; 2021."},{"issue":"25","key":"14094_CR13","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2\u2013positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366\u201373.","journal-title":"J Clin Oncol"},{"issue":"9472","key":"14094_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet"},{"issue":"14","key":"14094_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"14094_CR16","unstructured":"Drugs and Medical Supplies Information Center. Ministry of Public Health,.Reference drug price 2024 [http:\/\/dmsic.moph.go.th\/dmsic"},{"key":"14094_CR17","unstructured":"Riewpaiboon A. Standard Cost List for Health Technology Assessment. 2010. Bangkok, Health Intervention and Technology Assessment Program (HITAP) 2013."},{"key":"14094_CR18","volume-title":"Development of an economic evaluation model for health promotion measures in thailand: A case study of alcohol consumption control measures., final report Edn","author":"S Patthara Lertwannawong","year":"2018","unstructured":"Patthara Lertwannawong S, Pilasant S, Duangthipsirikul A, Poonchai. Development of an economic evaluation model for health promotion measures in thailand: A case study of alcohol consumption control measures., final report Edn. Nonthaburi: Health Intervention and Technology Assessment Program (HITAP); 2018."},{"issue":"Suppl 5","key":"14094_CR19","first-page":"52","volume":"13","author":"J Hornberger","year":"2002","unstructured":"Hornberger J, Kerrigan M, Foutel V. Cost-effectiveness of trastuzumab (Herceptin) for treatment of metastatic breast cancer. Ann Oncol. 2002;13(Suppl 5):52.","journal-title":"Ann Oncol"},{"issue":"5","key":"14094_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1524-4733.2009.00511.x","volume":"12","author":"C Skedgel","year":"2009","unstructured":"Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2\/Neu\u2010positive breast cancer: an analysis based on updated results from the HERA trial. Value Health. 2009;12(5):641\u20138.","journal-title":"Value Health"},{"issue":"2","key":"14094_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5114\/wo.2013.34624","volume":"17","author":"J Huszno","year":"2013","unstructured":"Huszno J, Le\u015b D, Sarzyczny-S\u0142ota D, Nowara E. Cardiac side effects of trastuzumab in breast cancer patients\u2013single centere experiences. Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia. 2013;17(2):190\u20135.","journal-title":"Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"issue":"16","key":"14094_CR22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14094-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:24:48Z","timestamp":1771597488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14094-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14094"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14094-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7344634\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study used secondary data from published sources and national databases; no human participants were directly involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}